retatrutide dosing clinical trials VisualAbstract: reduces body weight by 17.5% in patients with obesity Efficacy and safety of retatrutide,

Back Brown, M, Goldstein, J, Podolsky, DK, et al (1 Sept 2020) 'In Memoriam: Dr

More serious risks include: Pancreatitis Gallbladder issues Risk of thyroid tumors (observed in rodent studies) Patients must weigh these risks carefully, especially when using the medication off-label

If they are willing to self-fund, self-funding SGLT-2 inhibitor ($80-100/month) is cheaper than self-funding GLP-1 agonists ($150-250/month) DPP-4 inhibitor (e.g

Emerging evidence positions GLP-1RAs as a transformative candidate for ocular therapeutics

It's hard to ignore all the buzz about GLP-1 medications, and now there's a growing class of GLP-1 supplements popping up everywhere